Neoadjuvant chemotherapy (NAC) has an important role in the treatment of breast cancer and the need for early detection of treatment response is high. Therefore we investigated the feasibility of using APT CEST at 7T as a biomarker for this purpose. Ten lesions were included and APT signal before and after the first cycle of NAC were correlated to the pathological response. Significant differences were found in APT signal corresponding with the pathological response. These results suggest that APT CEST may be used to predict the response to NAC treatment in an early stage.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords